AbCellera Biologics (8QQ) Ownership - Who Owns AbCellera Biologics?
AbCellera Biologics (8QQ) Ownership Overview
- 38.60% Insiders
- 5.12% Mutual Funds
- 0.43% Other Institutional Investors
- 1.52% ETFs
- 54.33% Public Companies and Individual Investors
The ownership structure of AbCellera Biologics (DE:8QQ) stock is a mix of institutional, retail, and individual investors. Approximately 7.07% of the company’s stock is owned by Institutional Investors, 38.60% is owned by Insiders, and 54.33% is owned by Public Companies and Individual Investors.
The ownership structure of AbCellera Biologics (DE:8QQ) stock is a mix of institutional, retail, and individual investors. Approximately 7.07% of the company’s stock is owned by Institutional Investors, 38.60% is owned by Insiders, and 54.33% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 23, 2026 | Michael R. Hayden | $570,442 | |
| Aug 17, 2026 | John S. Montalbano | $110,300 | |
| Aug 13, 2026 | Michael R. Hayden | $481,033 | |
| Aug 13, 2026 | Andrew Booth | $383,904 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | €881,805 | |
| Dec 31, 2025 | Driehaus Capital Management Llc | €12,900,236 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Carl L. G. Hansen | 56,984,009 | Insider | 17.59% | 721,531,522 |
| Thermopylae Holdings Ltd. | 56,134,097 | Insider | 17.32% | 710,769,936 |
| Felix Baker | 33,012,138 | Institution | 10.19% | 417,999,691 |
| Smallcap World Fund Inc | 13,228,596 | Institution | 4.08% | 167,500,483 |
| Veronique Lecault | 9,613,674 | Insider | 2.97% | 121,728,340 |
| Ishares | 3,576,270 | Institution | 1.10% | 45,282,731 |
| Steve Weber | 2,864,729 | Institution | 0.88% | 36,273,199 |
| Blackrock Funds | 1,579,315 | Institution | 0.49% | 19,997,287 |
| Michael R. Hayden | 1,491,642 | Insider | 0.46% | 18,887,171 |
| T. Rowe Price New Horizons Fund, Inc. | 1,053,900 | Institution | 0.33% | 13,344,482 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Smallcap World Fund Inc | 13,228,596 | Institution | 4.08% | 167,500,483 |
| Blackrock Funds | 1,579,315 | Institution | 0.49% | 19,997,287 |
| T. Rowe Price New Horizons Fund, Inc. | 1,053,900 | Institution | 0.33% | 13,344,482 |
| Fidelity Concord Street Trust | 255,753 | Institution | 0.08% | 3,238,344 |
| Driehaus Mutual Funds | 246,560 | Institution | 0.08% | 3,121,943 |
| Valic Co I | 88,993 | Institution | 0.03% | 1,126,829 |
| Lazard Funds Inc | 58,472 | Institution | 0.02% | 740,372 |
| Brinker Capital Destinations Trust | 35,919 | Institution | 0.01% | 454,806 |
| Usaa Mutual Funds Trust | 29,481 | Institution | <0.01% | 373,288 |
| American Century Etf Trust | 4,396 | Institution | <0.01% | 55,662 |
FAQ
Who Owns AbCellera Biologics (DE:8QQ)?
According to the latest TipRanks data, approximately 7.07% of the company's stock is held by institutional investors, 38.60% is held by insiders, and 54.33% is held by public companies and individual investors.
What percentage of AbCellera Biologics (DE:8QQ) stock is held by institutional investors?
According to the latest TipRanks data, approximately 7.07% of AbCellera Biologics (DE:8QQ) stock is held by institutional investors: 5.12% by mutual funds, 1.52% by ETFs and 0.43% by other institutional investors.
What percentage of AbCellera Biologics (DE:8QQ) stock is held by retail investors?
According to the latest TipRanks data, approximately 54.33% of AbCellera Biologics (DE:8QQ) stock is held by public companies and individual investors.
Who owns the most shares of AbCellera Biologics (DE:8QQ)?
Carl L. G. Hansen owns the most shares of AbCellera Biologics (DE:8QQ).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.